Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease

NCT01129557 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT01129557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease
Lead sponsor
Columbia University
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2009
Completion date
December 31, 2012
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy, focal segmental glomerulosclerosis, glomerulonephritis, membranous, glomerulopathy (obesity-associated), hypertensive nephrosclerosis, iga nephropathy, proteinuric kidney disease